Erratum: Tyrosine Nitration of PA700 Links Proteasome Activation to Endothelial Dysfunction in Mouse Models with Cardiovascular Risk Factors (PLoS ONE (2012) 7:1 (e29649) DOI: 10.1371/journal.pone.0029649);Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Xu, Jian ^a   Wang, Shuangxi ^a   Zhang, Miao ^a   Wang, Qilong ^a   Asfa, Sima ^a   Zou, Ming Hui ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26S PROTEASOME; ACETYLCHOLINE; ANGIOTENSIN II; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXYNITRITE; PROTEASOME; PROTEIN PA700; REGULATOR PROTEIN; SMALL INTERFERING RNA; STREPTOZOCIN; THIOREDOXIN; TYROSINE; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN; PEROXYNITROUS ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; LIPID DIET; MALE; MOUSE; NITRATION; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; STREPTOZOCIN DIABETES; VASODILATATION; ANIMAL; C57BL MOUSE; CARDIOVASCULAR DISEASE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; MOUSE MUTANT; NITROSATION; PATHOPHYSIOLOGY; PROTEIN SUBUNIT; RISK FACTOR; RNA INTERFERENCE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; LEUPEPTINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROSATION; PEROXYNITROUS ACID; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; RECEPTORS, LDL; RISK FACTORS; RNA INTERFERENCE; THIOREDOXINS; TYROSINE;

EID: 84855857580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0286134     Document Type: Erratum

References (52)

1. Szabo C, Ischiropoulos H, Radi R, (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662-680.
2. Pacher P, Beckman JS, Liaudet L, (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
3. Hershko A, Ciechanover A, (1992) The ubiquitin system for protein degradation. Annu Rev Biochem 61: 761-807.
4. Demartino GN, Gillette TG, (2007) Proteasomes: machines for all reasons. Cell 129: 659-662.
5. Chu-Ping M, Vu JH, Proske RJ, Slaughter CA, DeMartino GN, (1994) Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20 S proteasome. J Biol Chem 269: 3539-3547.
6. Thompson D, Hakala K, DeMartino GN, (2009) Subcomplexes of PA700, the 19 S regulator of the 26 S proteasome, reveal relative roles of AAA subunits in 26 S proteasome assembly and activation and ATPase activity. J Biol Chem 284: 24891-24903.
7. Li X, Demartino GN, (2009) Variably modulated gating of the 26S proteasome by ATP and polyubiquitin. Biochem J 421: 397-404.
8. Adams GM, Crotchett B, Slaughter CA, DeMartino GN, Gogol EP, (1998) Formation of proteasome-PA700 complexes directly correlates with activation of peptidase activity. Biochemistry 37: 12927-12932.
9. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
10. Herrmann J, Soares SM, Lerman LO, Lerman A, (2008) Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll Cardiol 51: 2003-2010.
11. Xu J, Wu Y, Song P, Zhang M, Wang S, et al. (2007) Proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 116: 944-953.
12. Xu J, Wang S, Wu Y, Song P, Zou MH, (2009) Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension. Hypertension 54: 625-632.
13. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, et al. (2005) Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol 16: 1005-1012.
14. Fekete MR, McBride WH, Pajonk F, (2005) Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer 5: 114.
15. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, et al. (2005) Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 112: 2677-2685.
16. Wang S, Xu J, Song P, Wu Y, Zhang J, et al. (2008) Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 52: 484-490.
17. Dong Y, Zhang M, Wang S, Liang B, Zhao Z, et al. (2010) Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes 59: 1386-1396.
18. Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP, (2003) A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol 21: 897-902.
19. Wang S, Zhang M, Liang B, Xu J, Xie Z, et al. (2010) AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 106: 1117-1128.
20. Nawa A, Fujita-Hamabe W, Nakamoto K, Tokuyama S, (2011) Nitric Oxide Synthase-mediated Alteration of Intestinal P-glycoprotein under Hyperglycemic Stress. Yakugaku Zasshi 131: 487-492.
21. Wang S, Xu J, Song P, Viollet B, Zou MH, (2009) In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 58: 1893-1901.
22. Whitsett J, Picklo MJ Sr, Vasquez-Vivar J, (2007) 4-Hydroxy-2-nonenal increases superoxide anion radical in endothelial cells via stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler Thromb Vasc Biol 27: 2340-2347.
23. Katusic ZS, d'Uscio LV, (2004) Tetrahydrobiopterin: mediator of endothelial protection. Arterioscler Thromb Vasc Biol 24: 397-398.
24. Altschmied J, Haendeler J, (2009) Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases. Antioxid Redox Signal 11: 1733-1740.
25. Ebrahimian T, Touyz RM, (2008) Thioredoxin in vascular biology: role in hypertension. Antioxid Redox Signal 10: 1127-1136.
26. Landmesser U, Drexler H, (2007) Endothelial function and hypertension. Curr Opin Cardiol 22: 316-320.
27. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, et al. (1979) Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 5: 211-224.
28. Dai S, He Y, Zhang H, Yu L, Wan T, et al. (2009) Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol 29: 495-502.
29. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, et al. (2004) Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res 94: 1483-1491.
30. World C, Spindel ON, Berk BC, (2011) Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-alpha: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol 31: 1890-1897.
31. Kusmierczyk AR, Kunjappu MJ, Kim RY, Hochstrasser M, (2011) A conserved 20S proteasome assembly factor requires a C-terminal HbYX motif for proteasomal precursor binding. Nat Struct Mol Biol 18: 622-629.
32. Roelofs J, Park S, Haas W, Tian G, McAllister FE, et al. (2009) Chaperone-mediated pathway of proteasome regulatory particle assembly. Nature 459: 861-865.
33. Tomko RJ Jr, Funakoshi M, Schneider K, Wang J, Hochstrasser M, (2010) Heterohexameric ring arrangement of the eukaryotic proteasomal ATPases: implications for proteasome structure and assembly. Mol Cell 38: 393-403.
34. Madura K, (2009) Cell biology: The proteasome assembly line. Nature 459: 787-788.
35. Young GW, Wang Y, Ping P, (2008) Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cardiovasc Med 18: 93-98.
36. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, et al. (2003) O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115: 715-725.
37. Furchgott RF, Zawadzki JV, (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376.
38. Xu J, Zou MH, (2009) Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120: 1266-1286.
39. Kim JA, Montagnani M, Koh KK, Quon MJ, (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113: 1888-1904.
40. Cooke JP, (1997) Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin Cardiol 20: II-45-51.
41. Grune T, Blasig IE, Sitte N, Roloff B, Haseloff R, et al. (1998) Peroxynitrite increases the degradation of aconitase and other cellular proteins by proteasome. J Biol Chem 273: 10857-10862.
42. Meininger CJ, Cai S, Parker JL, Channon KM, Kelly KA, et al. (2004) GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. Faseb J 18: 1900-1902.
43. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM, (2004) Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 24: 445-450.
44. Reimers JI, Andersen HU, Mauricio D, Pociot F, Karlsen AE, et al. (1996) Strain-dependent differences in sensitivity of rat beta-cells to interleukin 1 beta in vitro and in vivo: association with islet nitric oxide synthesis. Diabetes 45: 771-778.
45. Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, et al. (2000) Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 123 (Pt 6): 1112-1121.
46. Jiang J, Cyr D, Babbitt RW, Sessa WC, Patterson C, (2003) Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP. J Biol Chem 278: 49332-49341.
47. Lorenz M, Wilck N, Meiners S, Ludwig A, Baumann G, et al. (2009) Proteasome inhibition prevents experimentally-induced endothelial dysfunction. Life Sci 84: 929-934.
48. Lorenz M, Hewing B, Hui J, Zepp A, Baumann G, et al. (2007) Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity. Faseb J 21: 1556-1564.
49. Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, et al. (2004) Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. Faseb J 18: 272-279.
50. Stangl K, Stangl V, (2010) The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res 85: 281-290.
51. Le Brocq M, Leslie SJ, Milliken P, Megson IL, (2008) Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal 10: 1631-1674.
52. Yen HC, Xu Q, Chou DM, Zhao Z, Elledge SJ, (2008) Global protein stability profiling in mammalian cells. Science 322: 918-923.